Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Double-Blind Single and Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of A4250 as Monotherapy, and in Combination With Colonic Release Cholestyramine (A3384) or Commercially Available Cholestyramine (Questran™) in Healthy Subjects

NCT02963077 is registered in ClinicalTrials.gov with Albireo as lead sponsor.

NCT NCT02963077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02963077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Double-Blind Single and Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of A4250 as Monotherapy, and in Combination With Colonic Release Cholestyramine (A3384) or Commercially Available Cholestyramine (Questran™) in Healthy Subjects
Lead sponsor
Albireo
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2013
Completion date
May 31, 2014
Enrollment
94 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

alagille syndrome, orphan cholestatic liver diseases, primary biliary cirrhosis, progressive familial intrahepatic cholestasis